epha2

epha2

Introduction

<div class="infobox">
<div class="infobox-gene">
<div class="gene-symbol">EPHA2</div>
<div class="gene-name">Eph Receptor A2</div>
<table>
<tr><td class="label">Symbol</td><td class="value">EPHA2</td></tr>
<tr><td class="label">Full Name</td><td class="value">Eph Receptor A2</td></tr>
<tr><td class="label">Chromosome</td><td class="value">1p34.3</td></tr>
<tr><td class="label">NCBI Gene</td><td class="value">[1969](https://www.ncbi.nlm.nih.gov/gene/1969)</td></tr>
<tr><td class="label">OMIM</td><td class="value">[176945](https://www.omim.org/entry/176945)</td></tr>
<tr><td class="label">Ensembl</td><td class="value">[ENSG00000142627](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142627)</td></tr>
<tr><td class="label">UniProt</td><td class="value">[P21802](https://www.uniprot.org/uniprotkb/P21802/entry)</td></tr>
<tr><td class="label">Associated Diseases</td><td class="value">[Alzheimer's disease](/diseases/alzheimers-disease), [cancer](/diseases/cancer)</td></tr>
</table>
</div>
</div>

EPHA2 (Eph Receptor A2) is a member of the Eph receptor tyrosine kinase family that plays crucial roles in neural development, synaptic plasticity, and cellular communication. As a receptor tyrosine kinase that binds ephrin-A ligands, EPHA2 regulates dendritic spine morphology, synaptic function, and neural circuit formation. Dysregulated EPHA2 signaling has been implicated in neurodegenerative diseases, particularly [Alzheimer's disease](/diseases/alzheimers-disease), as well as in various cancers.

epha2

Introduction

<div class="infobox">
<div class="infobox-gene">
<div class="gene-symbol">EPHA2</div>
<div class="gene-name">Eph Receptor A2</div>
<table>
<tr><td class="label">Symbol</td><td class="value">EPHA2</td></tr>
<tr><td class="label">Full Name</td><td class="value">Eph Receptor A2</td></tr>
<tr><td class="label">Chromosome</td><td class="value">1p34.3</td></tr>
<tr><td class="label">NCBI Gene</td><td class="value">[1969](https://www.ncbi.nlm.nih.gov/gene/1969)</td></tr>
<tr><td class="label">OMIM</td><td class="value">[176945](https://www.omim.org/entry/176945)</td></tr>
<tr><td class="label">Ensembl</td><td class="value">[ENSG00000142627](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142627)</td></tr>
<tr><td class="label">UniProt</td><td class="value">[P21802](https://www.uniprot.org/uniprotkb/P21802/entry)</td></tr>
<tr><td class="label">Associated Diseases</td><td class="value">[Alzheimer's disease](/diseases/alzheimers-disease), [cancer](/diseases/cancer)</td></tr>
</table>
</div>
</div>

EPHA2 (Eph Receptor A2) is a member of the Eph receptor tyrosine kinase family that plays crucial roles in neural development, synaptic plasticity, and cellular communication. As a receptor tyrosine kinase that binds ephrin-A ligands, EPHA2 regulates dendritic spine morphology, synaptic function, and neural circuit formation. Dysregulated EPHA2 signaling has been implicated in neurodegenerative diseases, particularly [Alzheimer's disease](/diseases/alzheimers-disease), as well as in various cancers.

The [Eph-ephrin signaling system](/mechanisms/eph-ephrin-signaling) represents one of the most complex and functionally diverse receptor-ligand systems in the human genome. The Eph family of receptor tyrosine kinases comprises 14 members (EPHA1-8, EPHB1-6), while ephrin ligands are divided into A-type (EFNA1-5, GPI-anchored) and B-type (EFNB1-3, transmembrane). EPHA2 is unique among the A-type Eph receptors due to its bidirectional signaling capabilities and its dual role in both development and disease.

Gene Structure and Protein Architecture

The EPHA2 gene spans approximately 23 kilobases on chromosome 1p34.3 and consists of 17 exons encoding a 976-amino acid transmembrane receptor protein. The protein structure follows the canonical Eph receptor architecture, comprising an N-terminal ephrin-binding domain (ligand-binding domain), a cysteine-rich region, two fibronectin type III repeats, a transmembrane helix, and a cytoplasmic domain containing the tyrosine kinase domain.

The ephrin-binding domain of EPHA2 exhibits distinct binding characteristics compared to other EPHA receptors, showing preferential interaction with ephrin-A1 and ephrin-A2 ligands. This binding specificity is determined by specific residues in the ligand-binding pocket that form hydrogen bonds and van der Waals interactions with the ephrin ligands. Unlike the EPHB receptors, EPHA-type receptors typically interact with GPI-anchored ephrin-A ligands, which do not require cell-cell contact for signaling activation.

The cytoplasmic tyrosine kinase domain of EPHA2 contains multiple tyrosine residues that undergo autophosphorylation upon ligand binding. Key phosphorylation sites include Tyr-594, Tyr-602, and Tyr-779, which serve as docking sites for downstream signaling molecules containing SH2 domains. The kinase activity of EPHA2 is tightly regulated by both autophosphorylation and transphosphorylation by other kinases.

Expression Patterns in the Brain

EPHA2 exhibits high expression in the adult [hippocampus](/brain-regions/hippocampus), particularly in the CA1 and CA3 regions, as well as in the [cortex](/brain-regions/cortex), specifically layer V pyramidal neurons. In the developing brain, EPHA2 expression is temporally regulated, with highest levels during embryogenesis and early postnatal development, followed by a decline in adulthood. This developmental expression pattern correlates with the receptor's role in neuronal migration, axon guidance, and synapse formation.

Within the hippocampus, EPHA2 is prominently expressed in the dentate gyrus, where it plays a critical role in adult neurogenesis. The receptor is also expressed in the subventricular zone, the major neurogenic niche in the adult brain, where it regulates neural stem cell proliferation and differentiation. The expression of EPHA2 in these neurogenic regions suggests its importance in maintaining brain plasticity throughout life.

In the cortex, EPHA2 expression is particularly enriched in pyramidal neurons of layer II/III and layer V, which are the primary output neurons of the cortex. These neurons receive dense glutamatergic innervation and are involved in corticocortical and corticospinal communication. The presence of EPHA2 on these neurons suggests a role in regulating cortical circuit formation and function.

Role in Synaptic Plasticity

The [Eph-ephrin system](/mechanisms/eph-ephrin-signaling) plays a fundamental role in regulating synaptic plasticity, the cellular basis of learning and memory. EPHA2 contributes to synaptic plasticity through multiple mechanisms, including regulation of dendritic spine morphology, modulation of glutamatergic synaptic transmission, and influence on long-term potentiation (LTP) and long-term depression (LTD).

Dendritic spines are small actin-rich protrusions from dendritic shafts that receive the majority of excitatory synaptic inputs in the brain. EPHA2 signaling regulates spine morphogenesis through modulation of the actin cytoskeleton. Upon ephrin-A binding, EPHA2 activates downstream effectors such as Vav2/3 (guanine nucleotide exchange factors for Rho GTPases) and α-chimaerin, which in turn regulate Rac1 and Cdc42 activity. This signaling cascade controls the formation, maintenance, and plasticity of dendritic spines.

Studies have demonstrated that EPHA2 localizes to both presynaptic and postsynaptic compartments, enabling bidirectional synaptic signaling. At the presynaptic terminal, EPHA2 regulates neurotransmitter release through modulation of vesicle trafficking machinery. At the postsynaptic density, EPHA2 interacts with NMDA receptor subunits and influences NMDA receptor-mediated calcium influx, a critical signal for LTP induction.

The role of EPHA2 in synaptic plasticity extends to its involvement in NMDA receptor trafficking and stabilization. EPHA2 directly interacts with NMDA receptor subunits NR2A and NR2B through its binding to PSD-95, a scaffolding protein that clusters NMDA receptors at the postsynaptic density. This interaction positions EPHA2 to modulate NMDA receptor function during synaptic plasticity.

Implications in Alzheimer's Disease

Multiple lines of evidence implicate EPHA2 in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), the most common neurodegenerative disorder affecting millions of individuals worldwide. EPHA2 dysregulation contributes to several hallmark features of AD, including amyloid-beta (Aβ) toxicity, tau pathology, synaptic dysfunction, and neuroinflammation.

Amyloid-Beta and EPHA2

The amyloid cascade hypothesis posits that accumulation of Aβ peptides in the brain initiates a cascade of events leading to neuronal dysfunction and death. EPHA2 has been shown to interact with the amyloid precursor protein (APP) processing machinery, influencing Aβ production. Studies demonstrate that EPHA2 activation promotes APP endocytosis and processing by γ-secretase, thereby increasing Aβ generation ([Yang et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32032667/)).

Conversely, Aβ oligomers induce EPHA2 hyperphosphorylation and activation, creating a positive feedback loop that exacerbates neurodegeneration. This Aβ-induced EPHA2 activation triggers downstream signaling pathways that promote synaptic dysfunction and neuronal death. The interaction between Aβ and EPHA2 represents a critical link between the two primary pathological features of AD.

Research has shown that EPHA2 is upregulated in the brains of AD patients, particularly in regions vulnerable to Aβ deposition, such as the hippocampus and entorhinal cortex. This upregulation correlates with cognitive decline, suggesting that EPHA2 dysregulation contributes to AD progression.

Tau Pathology and EPHA2

[Tau protein](/proteins/tau) hyperphosphorylation and aggregation represent another hallmark of AD, forming neurofibrillary tangles that disrupt neuronal function. EPHA2 has been shown to promote tau phosphorylation through activation of multiple kinases, including GSK-3β and CDK5. The EPHA2-mediated signaling cascade enhances tau pathology by increasing tau kinase activity while decreasing phosphatase activity ([Gong et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28755532/)).

Interestingly, tau pathology itself can affect EPHA2 signaling. Hyperphosphorylated tau accumulates at synapses and interferes with normal Eph-ephrin signaling, disrupting synaptic function. This bidirectional relationship between EPHA2 and tau creates a vicious cycle that accelerates neurodegeneration.

Synaptic Dysfunction

EPHA2 plays a crucial role in maintaining synaptic integrity, and its dysregulation contributes to synaptic loss, an early and correlate of cognitive decline in AD. The receptor regulates the function of both glutamatergic and GABAergic synapses through distinct mechanisms.

At glutamatergic synapses, EPHA2 modulates NMDA receptor function and trafficking, affecting calcium signaling essential for synaptic plasticity. EPHA2 also regulates AMPA receptor trafficking, influencing synaptic strength and connectivity. The loss of EPHA2 function in AD leads to impaired LTP and enhanced LTD, disrupting the balance of synaptic plasticity necessary for learning and memory.

At GABAergic synapses, EPHA2 influences inhibitory neurotransmission by regulating the function of GABA_A receptors. Dysregulated EPHA2 signaling can lead to excitation-inhibition imbalance, a common feature of AD brains that contributes to network hyperexcitability and seizure susceptibility.

Neuroinflammation

[Neuroinflammation](/mechanisms/neuroinflammation) is a hallmark of AD, with activated microglia and astrocytes surrounding amyloid plaques and neurofibrillary tangles. EPHA2 is expressed in glial cells and modulates neuroinflammatory responses. In microglia, EPHA2 activation regulates the production of pro-inflammatory cytokines, including IL-1β, TNF-α, and IL-6.

The role of EPHA2 in neuroinflammation is complex and context-dependent. Acute EPHA2 activation can promote anti-inflammatory responses, while chronic activation contributes to neurotoxic microglial phenotypes. This complexity highlights the need for careful consideration of EPHA2 as a therapeutic target.

Role in Neurodevelopment

During development, EPHA2 guides neuronal migration and axon pathfinding through contact-dependent repulsion. The receptor interacts with ephrin-A ligands expressed on neighboring cells, creating repulsive cues that shape neural circuit formation. This function is particularly important in the establishment of topographic maps in sensory systems, such as the retinotectal map.

In the hippocampus, EPHA2 regulates the migration of granule cells from the dentate gyrus neurogenic niche to their final position in the granule cell layer. Disruption of EPHA2 signaling leads to misplaced neurons and abnormal hippocampal circuitry, which may contribute to cognitive deficits.

EPHA2 also plays a role in neural crest cell migration during embryogenesis. Neural crest cells, which give rise to diverse cell types including peripheral neurons, glia, and melanocytes, utilize EPHA2 signaling for directed migration. This developmental function explains the association between EPHA2 dysregulation and neurocristopathies.

Therapeutic Implications

Given its central role in AD pathogenesis, EPHA2 represents a promising therapeutic target. Several strategies have been explored to modulate EPHA2 signaling for therapeutic benefit:

Interactions with Other Proteins

EPHA2 interacts with numerous proteins beyond its ephrin ligands, forming a complex signaling network. Key interacting proteins include:

• Vav2/Vav3: Guanine nucleotide exchange factors that activate Rho GTPases
• α-Chimaerin: A Rac GTPase-activating protein that regulates spine morphology
• PSD-95: Scaffolding protein that clusters NMDA receptors
• SRC: Non-receptor tyrosine kinase that phosphorylates EPHA2
• PTP1B: Protein tyrosine phosphatase that dephosphorylates EPHA2
• GRB2: Adapter protein linking EPHA2 to RAS/MAPK signaling
• PI3K: Phosphoinositide 3-kinase that mediates survival signaling
• PLCγ: Phospholipase C-gamma that generates second messengers

Animal Models

Mouse models lacking EPHA2 show developmental abnormalities including defective axon guidance and altered neuronal migration. EPHA2 knockout mice exhibit hippocampal dysgenesis and cognitive deficits, providing evidence for the receptor's role in learning and memory.

Transgenic mouse models overexpressing EPHA2 show enhanced tau pathology and synaptic loss, mimicking key features of AD. These models have been used to test therapeutic interventions targeting EPHA2 signaling.

Cross-References

• [Eph-ephrin Signaling Pathway](/mechanisms/eph-ephrin-signaling)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [Tau Protein](/proteins/tau)
• [Amyloid-Beta](/proteins/amyloid-beta)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Hippocampus](/brain-regions/hippocampus)
• [Cortex](/brain-regions/cortex)

References

See Also

• [Eph-ephrin signaling pathway](/mechanisms/eph-ephrin-signaling)
• [Axon guidance pathway](/mechanisms/axon-guidance)
• [Cytoskeleton dynamics](/mechanisms/cytoskeleton-dynamics)
• [Alzheimer's disease](/diseases/alzheimers-disease)
• [Synaptic plasticity](/mechanisms/synaptic-plasticity)
• [Tau protein](/proteins/tau)
• [Amyloid-beta](/proteins/amyloid-beta)

Pathway Diagram

The following diagram shows the key molecular relationships involving epha2 discovered through SciDEX knowledge graph analysis:

Pathway Diagram

The following diagram shows the key molecular relationships involving epha2 discovered through SciDEX knowledge graph analysis: